Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy
about
Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally AdvCombination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
P2860
Q34428153-727789B5-75C5-4EE5-A13E-1EF67903179BQ36452222-DDD02847-3A17-4A48-AF73-1070CAA86137Q36896150-C708E9C6-62AD-4900-B5E3-8F792F7EA5DEQ37665397-B4EAAA6D-30AB-4532-8DC1-B76AAAF0D380Q39292642-22DD701A-CA5B-4D7E-88F4-14A9B2D7F723Q39435767-DA9950B3-D8CE-4585-BA5C-C6E02342BE80Q40453735-2B8D2276-F7F9-47D9-A2D1-BBE0BD15A90CQ44417765-3C93B166-0328-4470-9833-E185C1D3BD8AQ50994494-35A38B15-EAF9-4106-B7AC-D2449D69303FQ53398198-3D8D930E-385C-4145-866A-6DDF0F0EB2A0
P2860
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weekly paclitaxel and trastuzu ...... predictive factor for efficacy
@en
Weekly paclitaxel and trastuzu ...... redictive factor for efficacy.
@nl
type
label
Weekly paclitaxel and trastuzu ...... predictive factor for efficacy
@en
Weekly paclitaxel and trastuzu ...... redictive factor for efficacy.
@nl
prefLabel
Weekly paclitaxel and trastuzu ...... predictive factor for efficacy
@en
Weekly paclitaxel and trastuzu ...... redictive factor for efficacy.
@nl
P2093
P2860
P1476
Weekly paclitaxel and trastuzu ...... predictive factor for efficacy
@en
P2093
Do-Youn Oh
Hye-Suk Han
In Ae Park
Jee Hyun Kim
Jin Hyun Park
Jin-Soo Kim
Keun-Wook Lee
Seock-Ah Im
So Yeon Park
Tae-You Kim
P2860
P304
P356
10.3346/JKMS.2009.24.5.910
P577
2009-09-24T00:00:00Z